ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates

分组1 - ARS Pharmaceuticals, Inc. reported a quarterly loss of $0.42 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.52 per share a year ago, indicating a significant decline [1] - The company posted revenues of $28.09 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 9.10%, but down from $86.58 million year-over-year [2] - The stock has underperformed, losing about 22.2% since the beginning of the year, while the S&P 500 has only declined by 1.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $25.86 million, and for the current fiscal year, it is -$1.41 on revenues of $177.14 million [7] - The Medical - Drugs industry, to which ARS Pharmaceuticals belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]